Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 2, 2012, Pages 139-151

  Cunningham, Morven ^a   Foster, Graham R ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antiviral agents; Hepatitis C; Interferon 2a; Protease inhibitors; Ribavirin

Indexed keywords

INTERLEUKIN 28B; NONSTRUCTURAL PROTEIN 1; PEGINTERFERON; RIBAVIRIN; RNA POLYMERASE; TELAPREVIR;

ANEMIA; ANORECTAL DISEASE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL DISEASE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER TRANSPLANTATION; MIXED INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; RASH; REVIEW; TREATMENT RESPONSE; VIRUS INFECTION;

EID: 84857533218     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11426895     Document Type: Review

References (47)

1. Alazawi W. Cunningham M. Dearden J. Foster G.R. (2010) Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 32: 344–355.
2. Alberti A. Chemello L. Benvegnu L. (1999) Natural history of hepatitis C. J Hepatol 31(Suppl. 1): 17–24.
3. Awad T. Thorlund K. Hauser G. Stimac D. Mabrouk M. Gluud C. (2010) Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 51: 1176–1184.
4. Bartels D.J. Zhou Y. Zhang E.Z. Marcial M. Byrn R.A. Pfeiffer T. et al. (2008) Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 198: 800–807.
5. Benhamou Y. Bochet M. Di Martino V. Charlotte F. Azria F. Coutellier A. et al. (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30: 1054–1058.
6. de Meyer S. Dierynck I. Ghys A. Beumont M. Daems B. van Baelen B. et al. (2011) Characterisation of HCV variants in non-SVR patients in the REALIZE study suggests that telaprevir exhibits a consistent resistance profile irrespective of a lead-in. J Hepatol 54(Suppl. 1): S475.
7. Dusheiko G.M. Fried M.W. Reddy R. Nelson D.R. Bzowej N. Adda N. et al. (2011) Telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virological response rates in treatment-naive patients regardless of race or ethnicity. J Hepatol 54(Suppl. 1): S167–S168.
8. Forestier N. Reesink H.W. Weegink C.J. McNair L. Kieffer T.L. Chu H.M. et al. (2007) Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46: 640–648.
9. Foster G.R. Hezode C. Bronowicki J.P. Carosi G. Weiland O. Verlinden L. et al. (2011 a) Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141: 881–889 e881.
10. Foster G.R. Zeuzem S. Andreone P. Pol S. Lawitz E.J. Diago M. et al. (2011 b) Subanalyses of the telaprevir lead-in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization. J Hepatol 54(Suppl. 1): S3–S4.
11. Fried M.W. Shiffman M.L. Reddy K.R. Smith C. Marinos G. Goncales F.L. Jr. et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982.
12. Garg V. van Heeswijk R. Lee J.E. Alves K. Nadkarni P. Luo X. (2011) Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54: 20–27.
13. Ge D. Fellay J. Thompson A.J. Simon J.S. Shianna K.V. Urban T.J. et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401.
14. Hadziyannis S.J. Sette H. Jr. Morgan T.R. Balan V. Diago M. Marcellin P. et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355.
15. Hezode C. Forestier N. Dusheiko G. Ferenci P. Pol S. Goeser T. et al. (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360: 1839–1850.
16. Hinrichsen H. Benhamou Y. Wedemeyer H. Reiser M. Sentjens R.E. Calleja J.L. et al. (2004) Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127: 1347–1355.
17. Jacobson I.M. Catlett I. Marcellin P. Bzowej N.H. Muir A.J. Adda N. et al. (2011 a) Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol 54(Suppl. 1): S542–S543.
18. Jacobson I.M. McHutchison J.G. Dusheiko G. Di Bisceglie A.M. Reddy K.R. Bzowej N.H. et al. (2011 b) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405–2416.
19. Jacobson I.M. McHutchison J.G. Dusheiko G.M. Di Bisceglie A.M. Reddy R. Bzowej N.H. et al. (2010) Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study. Hepatology 52(Suppl. 1), DOI: 10.002/hep.2397910.002/hep.23979.
20. Kieffer T.L. Sarrazin C. Miller J.S. Welker M.W. Forestier N. Reesink H.W. et al. (2007) Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46: 631–639.
21. Lawitz E. Rodriguez-Torres M. Muir A.J. Kieffer T.L. McNair L. Khunvichai A. et al. (2008) Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 49: 163–169.
22. Lin K. Perni R.B. Kwong A.D. Lin C. (2006) VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 50: 1813–1822.
23. Manns M.P. McHutchison J.G. Gordon S.C. Rustgi V.K. Shiffman M. Reindollar R. et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965.
24. Marcellin P. (2009) Hepatitis B and hepatitis C in 2009. Liver Int 29(Suppl. 1): 1–8.
25. Marcellin P. Forns X. Goeser T. Ferenci P. Nevens F. Carosi G. et al. (2011) Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 140: 459–468 e451; quiz e414.
26. McHutchison J.G. Everson G.T. Gordon S.C. Jacobson I.M. Sulkowski M. Kauffman R. et al. (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360: 1827–1838.
27. McHutchison J.G. Manns M. Patel K. Poynard T. Lindsay K.L. Trepo C. et al. (2002) Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061–1069.
28. McHutchison J.G. Manns M.P. Muir A.J. Terrault N.A. Jacobson I.M. Afdhal N.H. et al. (2010) Telaprevir for previously treated chronic HCV infection. N Engl J Med 362: 1292–1303.
29. Morikawa K. Lange C.M. Gouttenoire J. Meylan E. Brass V. Penin F. et al. (2011) Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J Viral Hepat 18: 305–315.
30. Pawlotsky J.M. (2011) Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus. Hepatology, DOI: 10.1002/hep.2426210.1002/hep.24262.
31. Perni R.B. Almquist S.J. Byrn R.A. Chandorkar G. Chaturvedi P.R. Courtney L.F. et al. (2006) Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 50: 899–909.
32. Pol S. Aerssens J. Zeuzem S. Andreone P. Lawitz E.J. Roberts S. et al. (2011) Similar SVR rates in IL28B CC, CT or TT prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. J Hepatol 54(Suppl. 1): S6–S7.
33. Reesink H.W. Zeuzem S. Weegink C.J. Forestier N. van Vliet A. van de Wetering de Rooij J. et al. (2006) Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131: 997–1002.
34. Sarrazin C. Kieffer T.L. Bartels D. Hanzelka B. Muh U. Welker M. et al. (2007) Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132: 1767–1777.
35. Sherman K.E. Flamm S.L. Afdhal N.H. Nelson D.R. Sulkowski M.S. Everson G.T. et al. (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365: 1014–1024.
36. Simmonds P. Holmes E.C. Cha T.A. Chan S.W. McOmish F. Irvine B. et al. (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74: 2391–2399.
37. Singal A.G. Waljee A.K. Shiffman M. Bacon B.R. Schoenfeld P.S. (2010) Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther 32: 969–983.
38. Soto B. Sanchez-Quijano A. Rodrigo L. del Olmo J.A. Garcia-Bengoechea M. Hernandez-Quero J. et al. (1997) Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 26: 1–5.
39. Sulkowski M. Dieterich D. Sherman K. Rockstroh J. Adda N. Mahnke L. et al. (2011 a) Interim analysis of a phase 2a double-blind study of TVR in combination with peg IFN-alpha2a and RBV in HIV/HCV co-infected patients. In Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, Available at: http://www.retroconference.org/2011/Abstracts/42467.htm.
40. Sulkowski M.S. Reddy R. Afdhal N.H. Di Bisceglie A.M. Zeuzem S. Poordad F. et al. (2011 b) Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir- based regimen in the ADVANCE and ILLUMINATE phase 3 studies. Journal of Hepatology 54(Suppl. 1): S195.
41. Sullivan J.C. de Meyer S. Bartels D.J. Dierynck I. Zhang E. Spanks J. et al. (2011) Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. J Hepatol 54(Suppl. 1): S4.
42. Tanaka Y. Nishida N. Sugiyama M. Kurosaki M. Matsuura K. Sakamoto N. et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105–1109.
43. Veldt B.J. Heathcote E.J. Wedemeyer H. Reichen J. Hofmann W.P. Zeuzem S. et al. (2007) Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147: 677–684.
44. Verbinnen T. van Marck H. Vandenbroucke I. Vijgen L. Claes M. Lin T.I. et al. (2010) Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol 84: 11124–11133.
45. Vermehren J. Sarrazin C. (2011) New HCV therapies on the horizon. Clin Microbiol Infect 17: 122–134.
46. Zeuzem S. Andreone P. Pol S. Lawitz E. Diago M. Roberts S. et al. (2011 a) Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417–2428.
47. Zeuzem S. Andreone P. Pol S. Lawitz E.J. Diago M. Roberts S. et al. (2011 b) REALIZE trial final results: telaprevir–based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ribavirin. J Hepatol 54(Suppl. 1): S3.